Blogs
Healthcare and Medtech Research Reports
Nov 10, 2025
In a significant milestone for the rare disease community, the FDA approved KYGEVVI (doxecitine and doxribtimine) in November 2025, marking the first and only approved treatment for thymidine kinase 2 deficiency (TK2d). This breakthrough approval represents a transformative moment for patients and families facing t...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper